BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 31185985)

  • 1. Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
    Callebout E; Ribeiro SM; Laurent S; De Man M; Ferdinande L; Claes KBM; Van der Meulen J; Geboes KP
    BMC Cancer; 2019 Jun; 19(1):567. PubMed ID: 31185985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy.
    Marks EI; Tan C; Zhang J; Zhou L; Yang Z; Scicchitano A; El-Deiry WS
    Cancer Biol Ther; 2015; 16(12):1710-9. PubMed ID: 26561209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiological complete response with regorafenib for multiple lung metastases of ascending colon cancer: a case report.
    Kikuchi K; Ogawa M; Sasaki A
    J Med Case Rep; 2024 Feb; 18(1):45. PubMed ID: 38321556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular insight of regorafenib treatment for colorectal cancer.
    Arai H; Battaglin F; Wang J; Lo JH; Soni S; Zhang W; Lenz HJ
    Cancer Treat Rev; 2019 Dec; 81():101912. PubMed ID: 31715423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survival in a patient with advanced lung adenocarcinoma harboring synchronous EGFR exon 18 G719A and BRAF V600E mutations and treated with afatinib: a case report.
    Huang Q; Chen C; Hu S; Wu H; Yu D; Zhu X; Xue C; Wu Y; Tang J; Xie R; Ran F
    Anticancer Drugs; 2022 Jan; 33(1):e730-e733. PubMed ID: 34387589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: A case report and literature review.
    Liu Y; Li M; Guo Y; Zhang Z; Du L; Zhang X; Wang Y; Zhang D; Xue L; Lei B; Su J; Zhang R; Chen J; Zhang X; Jia Q; Tian C
    Pathol Res Pract; 2024 Jul; 259():155371. PubMed ID: 38820929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic
    Huang Y; Zhang S; Hu X; Wang X; Zhao Y; Li Z
    AME Case Rep; 2024; 8():38. PubMed ID: 38711893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib.
    Rechsteiner M; Wild P; Kiessling MK; Bohnert A; Zhong Q; Stahel RA; Moch H; Curioni-Fontecedro A
    Ann Oncol; 2015 Jan; 26(1):246-248. PubMed ID: 25336117
    [No Abstract]   [Full Text] [Related]  

  • 9. Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation: A rare case report.
    Liao L; Cheng Q; Zhu G; Pei F; Ye S
    Medicine (Baltimore); 2020 May; 99(21):e20026. PubMed ID: 32481270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the best treatment options for BRAF-mutant metastatic colon cancer.
    Taieb J; Lapeyre-Prost A; Laurent Puig P; Zaanan A
    Br J Cancer; 2019 Sep; 121(6):434-442. PubMed ID: 31353365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients with Metastatic Colorectal Cancer Who Have Failed First-Line Therapy.
    Gambaro K; Marques M; McNamara S; Couetoux du Tertre M; Hoffert C; Srivastava A; Schab A; Alcindor T; Langleben A; Sideris L; Abdelsalam M; Tehfe M; Couture F; Batist G; Kavan P
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging treatment options for
    Ursem C; Atreya CE; Van Loon K
    Gastrointest Cancer; 2018; 8():13-23. PubMed ID: 29628780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axillary cutaneous metastasis of colon cancer with microsatellite instability-high and BRAF V600E mutation treated with curative-intent surgery: a case report.
    Yamai D; Shimada Y; Ozeki H; Matsumoto A; Abe K; Tajima Y; Nakano M; Ichikawa H; Sakata J; Wakai T
    Surg Case Rep; 2023 Nov; 9(1):196. PubMed ID: 37962682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric SHP2 inhibition enhances regorafenib's effectiveness in colorectal cancer treatment.
    Han X; Wang W; Wang R; Zhang W; Zhu L; Xu Q; Guo W; Gu Y
    Biochem Biophys Res Commun; 2024 May; 709():149812. PubMed ID: 38564942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib in Patients With Solid Tumors With
    Sahai V; Rothe M; Mangat PK; Garrett-Mayer E; Suhag V; Dib EG; Mehmi I; Kadakia KC; Pisick E; Duvivier HL; Le P; Li R; Michelin DP; Wilcox RE; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
    JCO Precis Oncol; 2024 Apr; 8():e2300527. PubMed ID: 38603652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Dynamic ctDNA Monitoring During Combination Therapies of BRAF V600E-Mutated Metastatic Colorectal Cancer: A Case Report.
    Wang Z; Ye CY; Zhou WL; Wang MM; Dai WP; Zheng J; Zang YS
    Onco Targets Ther; 2020; 13():11849-11853. PubMed ID: 33235471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600E-mutated Colorectal Neuroendocrine Carcinoma Effectively Treated with a Chemotherapy Protocol for BRAF-mutated Metastatic Colorectal Cancer: A Case Report.
    Owaki S; Mori Y; Nakai S; Maeda H; Imazu M; Tomita Y; Kanaiwa H; Yamaguchi A; Kitagawa M; Hirano A; Kimura Y; Tsuchida K; Kataoka H
    Intern Med; 2023 Nov; ():. PubMed ID: 37981300
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Gao C; Esni F; Chu E; Hu J
    Biochem Biophys Rep; 2024 Mar; 37():101634. PubMed ID: 38188365
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumor Lysis Syndrome in a Patient with BRAF
    Kasai S; Sato E; Sakaguchi C; Sasaki Y
    Intern Med; 2024 Apr; ():. PubMed ID: 38631859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Two Cases of the Significant Liver Damage by Regorafenib].
    Machida T; Yoshida M; Saiga H; Koide T; Matsumoto A; Wada T; Tanaka H; Harada N; Mitsutsuji M; Samizo M
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1600-1602. PubMed ID: 38303354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.